Post-exposure prophylaxis with rVSV-ZEBOV following exposure to a patient with Ebola virus disease relapse in the UK: an operational, safety and immunogenicity report by Davis, Chris et al.
Ac
ce
pte
d M
an
us
cri
pt
 
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of 
America. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Post-exposure prophylaxis with rVSV-ZEBOV following exposure to a 
patient with Ebola virus disease relapse in the UK: an operational, 
safety and immunogenicity report 
Authors 
Chris Davis* MRC-University of Glasgow Centre for Virus Research, Glasgow, UK  
Chris.Davis@glasgow.ac.uk 
Tom Tipton* Porton Down, National Infection Service, Public Health England, Salisbury, UK 
Tom.Tipton@phe.gov.uk 
Suleman Sabir MRC-University of Glasgow Centre for Virus Research, Glasgow, UK 
Suleman.Sabir@glasgow.ac.uk 
Celia Aitken West of Scotland Specialist Virology Centre, Glasgow Royal Infirmary, Glasgow, UK 
billandcelia@sky.com 
Susan Bennett West of Scotland Specialist Virology Centre, Glasgow Royal Infirmary, Glasgow, UK 
Susan.Bennett@ggc.scot.nhs.uk 
Stephan Becker Institute of Virology, Philipps University Marburg, Germany  
becker@staff.uni-marburg.de 
Tom Evans Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow 
t.j.evans@udcf.gla.ac.uk 
Sarah Katharina Fehling Institute of Virology, Philipps University Marburg, Germany 
fehling@staff.uni-marburg.de 
Rory Gunson West of Scotland Specialist Virology Centre, Glasgow Royal Infirmary, Glasgow, UK 
rory.gunson@ggc.scot.nhs.uk 
Yper Hall Porton Down, National Infection Service, Public Health England, Salisbury, UK 
Yper.Hall@phe.gov.uk 
Celia Jackson West of Scotland Specialist Virology Centre, Glasgow Royal Infirmary, Glasgow, UK & 
Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, UK 
Celia.Jackson@ggc.scot.nhs.uk 
Ingolfur Johanssen Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK 
Ingolfur.Johannessen@nhslothian.scot.nhs.uk 
Marie Paule Kieny World Health Organisation World Health Organization, Geneva, Switzerland & 
Inserm, Paris, France  
marie-paule.kieny@inserm.fr kienym@who.int 
Jim McMenamin Health Protection Scotland, Glasgow, UK 
jim.mcmenamin@nhs.net 
Elizabeth Spence Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, 
UK 
Liz.Spence@glasgow.ac.uk 
Thomas Strecker Institute of Virology, Philipps University Marburg, Germany  
strecker@staff.uni-marburg.de 
Catie Sykes Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, UK 
catie.sykes@nhs.net 
Kate Templeton Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1165/5648103 by U
niversity of G
lasgow
 user on 06 January 2020
Ac
ce
pte
d M
an
us
cri
pt
 
2 
 
Kate.Templeton@nhslothian.scot.nhs.uk 
Fiona Thorburn Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow & 
West of Scotland Specialist Virology Centre, Glasgow Royal Infirmary 
fionathorburn@nhs.net 
Erica Peters Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow 
Erica.Peters@ggc.scot.nhs.uk 
Ana Maria Henao Restrepo World Health Organisation, Geneva, Switzerland & Inserm, Paris, France 
henaorestrepoa@who.int 
Beth White Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, UK 
beth.white@ggc.scot.nhs.uk 
Maria Zambon Public Health England Colindale, London, UK  
maria.zambon@phe.gov.uk 
Miles W. Carroll Porton Down, National Infection Service, Public Health England, Salisbury, UK 
miles.carroll@phe.gov.uk 
Emma C. Thomson MRC-University of Glasgow Centre for Virus Research, Glasgow, UK & 
Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, UK 
emma.thomson@glasgow.ac.uk 
 
*Contributed equally to the manuscript 
Corresponding author 
Dr. Emma Thomson emma.thomson@glasgow.ac.uk   
MRC-University of Glasgow Centre for Virus Research 
Stoker Building room 302 
464 Bearsden Road 
Glasgow   
M: +44 7870 653 680  
T:  +44 (0)141 330 2928  
Fax: +44(0) 141 330 2271  
 
Summary: The rVSV-ZEBOV vaccine was used as post-exposure prophylaxis in individuals exposed to 
Ebola virus in the UK. It was rolled out rapidly and was generally well-tolerated. Side effects 
correlated with the magnitude of CD8+ T cell responses. 
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Abstract 
Background 
In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late 
reactivation of Ebola virus disease (EVD) in the UK. Vaccination was offered to 45 individuals with an 
initial assessment of high exposure risk.  
Methods 
Approval for rapid expanded access to the recombinant vesicular stomatitis virus–Zaire Ebola virus 
vaccine (rVSV-ZEBOV) as an unlicensed emergency medicine was obtained from the relevant 
authorities. An observational follow-up study was carried out for 1 year following vaccination.  
Results 
26/45 individuals elected to receive vaccination between October 10th and 11th 2015 following 
written informed consent. By day 14, 39% had seroconverted, rising to 87% by day 28 and 100% by 3 
months, although these responses were not always sustained. Neutralising antibody responses were 
detectable in 36% by day 14 and 73% at 12 months. Common side effects included fatigue, myalgia, 
headache, arthralgia and fever. These were positively associated with glycoprotein (GP)-specific T-
cell but not IgM or IgG antibody responses. No severe vaccine-related adverse events were reported. 
No-one exposed to the virus became infected. 
Conclusions 
This paper reports the use of the rVSV-ZEBOV vaccine given as an emergency intervention to 
individuals exposed to a patient presenting with a late reactivation of EVD. The vaccine was 
relatively well tolerated but a high percentage developed a fever ≥37.5oC necessitating urgent 
screening for Ebola virus and a small number developed persistent arthralgia.  
Keywords: Ebola virus, rVSV-ZEBOV, vaccine, T cell  
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Introduction 
The 2013-2016 Ebola virus (EBOV) outbreak in West Africa resulted in 28,646 reported cases of Ebola 
virus disease (EVD) and 11,323 deaths[1]. Healthcare workers were at particularly high-risk of 
infection with at least 500 deaths among 900 cases and amplified transmission of the disease in 
some healthcare settings. On the 29th December 2014, a nurse who had worked in a treatment 
centre in Sierra Leone was diagnosed with EVD on return to the UK[2]. Full protocols for the 
management of viral haemorrhagic fever (VHF) were instituted immediately. Of 3 individuals 
providing direct healthcare to the patient prior to transfer to the UK high level isolation unit, none 
were categorised as high-risk due to appropriate use of personal protective equipment (PPE). In 
contrast, when the same patient became unwell with a previously unreported complication of EVD 
reactivation associated with meningo-encephalitis between the 5th-9th October 2015 (the only 
reported late reactivation resulting in detectable viremia of 28,646 cases), 45 healthcare workers 
and household contacts were initially categorised as high-risk. An incident management team (IMT) 
was set up in order to consider post-exposure prophylaxis (PEP). 
In October 2015, no licensed EBOV-PEP was available although vaccine responses had been shown 
to occur rapidly in macaques and humans. An interim phase III cluster randomised trial of the 
replication competent rVSV-ZEBOV vaccine, published in July 2015, indicated 100% efficacy at 10 
days post-vaccination and an acceptable side effect profile[3]. In rhesus macaques, it was found to 
provide protection when given as little as 1 week prior to exposure[4] and had also been used 
successfully as PEP 49 hours after exposure in a laboratory worker following a high titre needlestick 
injury[5]. Another6 individuals subsequently received the vaccine following exposure during the 
2013-2016 outbreak and none developed EVD[6].  
In view of the evidence of a rapid immune response in vaccinated individuals and the reported 
safety of the rVSV-ZEBOV vaccine, a decision was made to offer vaccination to those with the highest 
exposure risk. Vaccinated individuals were subsequently enrolled into the Glasgow Ebola Vaccine 
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Follow-up Study (GEVS). Primary outcomes included evidence of infection with EBOV, the immune 
response following vaccination and side effects. 
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Methods 
Approval process: An international IMT including infection experts from Europe and the USA 
recommended that vaccination be offered to those with highest exposure risk on the 9th October 
2015, following EVD diagnosis in the index case (Figure 1). 65 individuals were identified by the 
Greater Glasgow and Clyde public health team and designated as category 1, 2 or 3 depending on 
their level of exposure following national guidance (Supplementary Table 1). These cases were re-
reviewed by 3 infectious diseases physicians, a public health physician and a clinical virologist, 
incorporating additional expert risk categorisation advice[7]. Those with a recent history of direct 
exposure to bodily fluids (vomit, diarrhoea, blood, sweat and/or cerebrospinal fluid) were recalled to 
an emergency vaccination clinic on 10th-11th October. 26/45 clinic attendees accepted the offer of 
vaccination with informed consent under local NHS emergency regulations for unlicensed 
treatments (Figure 2). The following day, the West of Scotland Research Ethics Committee approved 
a prospective observational follow-up study (15/WS/0251).    
Vaccination: The vaccine clinic was staffed by 6 doctors, 4 nurses and a receptionist. Any attendee 
with a temperature of ≥37.5oC on arrival was immediately screened for EBOV by staff in full PPE 
(Tyvek suit, rubber boots, overshoes, FFP3 mask, visor, double gloves and apron) (Supplementary 
Figure 1). EBOV PCR was carried out within 6 hours of dispatch at Edinburgh Royal Infirmary. 
Vaccination protocols (Supplementary Information)[3] and rVSV-ZEBOV vaccine were provided by 
WHO and maintained at -80oC. A single dose of 2x107 plaque-forming units (pfu)/ml was prepared 
using the PREVAIL pharmacy manual [8] and administered intramuscularly in the deltoid muscle.   
Clinical follow-up: all individuals with a category 3 exposure were followed up with daily 
temperature screening for 3 weeks. Those with a temperature of ≥37.5oC were tested for EBOV 
infection by RT-PCR. Vaccinated individuals were followed-up at 30 minutes, 14 days and 1, 3, 6, 9 
and 12 months post-vaccination. 20ml of blood, urine and sputum samples and a semen sample 
from males was obtained at each clinic visit.   
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Laboratory methods 
PCR: Samples obtained during fever and at days 14 and 28 following vaccination were tested at 
Edinburgh Royal Infirmary using an adapted version of the Trombley PCR assay[9]. Blood, urine and 
semen were tested for the presence of the rVSV-ZEBOV vaccine using a VSV RT-PCR [10]. EAV was 
used as an internal control and had a detection limit of between 50-5pfu/ml. Plasma, urine, sputum, 
serum, saliva, semen and whole blood were extracted using the NucliSens EasyMAG (bioMérieux, 
Hampshire, UK) according to manufacturer’s instructions. PCR was performed on 6μl of RNA extract 
with the Platinum RT-PCR mastermix kit (Invitrogen) on an ABI Prism 7500 SDS real-time platform 
(Applied Biosystems) in a 15μl reaction volume. The following thermal profile was used: 15min at 
50oC and then 95oC for 15min, followed by 40 cycles of 95oC for 60s and 60oC for 60s. 
Immunological assays: Antibody assays were carried out at days 14, 28 and 3, 6, 9 and 12 months 
post-vaccination and T-cell responses measured by IFNγ ELISpot and flow cytometry at 1, 3, 6, 9 and 
12 months. 
Enzyme linked-immunosorbent assay (ELISA)[11] 
High binding microtiter plates were coated with 1µg/ml EBOV GP and incubated for 16-20 hours. 
Following washing (PBS/0.1% Tween20) and blocking (Casein), 1:200 dilutions of plasma sample 
were added and incubated for two hours. Polyclonal anti-human IgG-AP antibody (1:1000) with 
substrate (diethanolamine substrate buffer with 20 mg pNPP in 20ml ddH2O) was used to develop 
the reaction. Optical density (OD) was determined at 405 nm. Samples were analysed in duplicate 
and background subtracted from the mean of each sample. Plates were read using a predefined 
softmax template which fits a 4-parameter logistic model to the dose response data, IU/ml are 
based on the WHO International Reference Standard (NIBSC 15/220) which was used to quantify the 
internal standard.  
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Neutralisation assays: Neutralization assays were performed at  biosafety level 4 at the Institute of 
Virology, Philipps-University Marburg, Germany as previously described[12]. Volunteer blood plasma 
was incubated at 56°C for 30 min for complement inactivation. After centrifugation at 13,000rpm for 
10 min, sera were serially diluted from 23-210 in Dulbecco's modified Eagle's medium (DMEM, Gibco) 
supplemented with 2% fetal calf serum (FCS, Gibco), penicillin (100U/ml), streptomycin (100mg/ml), 
and L-glutamine (2mmol/l) (Invitrogen) in 96-well culture plates. 100 TCID50 units of EBOV (Zaire, 
isolate Mayinga, AF086833) were added to the serum dilutions. Following incubation at 37°C for one 
hour, Vero cell suspension in DMEM containing 2% FCS was added and incubated at 37°C with 5% 
CO2. Cytopathic effects (CPE) were evaluated at seven days post infection. Neutralization titers were 
calculated as GMT of four replicates.  
IFNγ-ELISpot assays: Peripheral blood mononuclear cell (PBMC)s  were thawed using warm media 
and rested overnight at 37°C. The following day they were stimulated with overlapping EBOV 
glycoprotein peptides (MP1/MP2) as previously described[13]. Plates were counted using an S6 core 
analyser (Cellular Technology Limited) and results adjusted to spot forming units (SFU)/1x106 
cells/ml. Analysis required detection of a positive control then subtraction of the non-peptide 
stimulated control from peptide-stimulated samples.   
T-cell phenotyping studies: Intracellular cytokine staining (ISC) was performed as previously 
described[13]. Briefly, PBMCs were re-suspended in warmed media and rested overnight at 37°C. 
The following day, cells were adjusted to 1x106cells/ml in media containing anti-CD28, CD49d and 
CD107a-PerCP cy5.5 (1 µg/ml). Cells were then untreated or stimulated with EBOV GP peptide pool, 
containing 187x15mer overlapping peptides at 2.5µg/peptide or 1µg/ml Staphylococcal Enterotoxin 
B peptide (SEB) for 16-18 hours. After two hours, brefeldin A and monensin (1µg/ml) were added to 
block cytokine secretion. The following day samples were washed and LIVE/DEAD dye added. 
Samples were washed, incubated with cell surface antibodies (CD3-APC 750, CD4-BV786, CD8-
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AF700, CD19- BV510 and then CD14-BV510, CCR7- APC, CD95-BV395 and CD45RO-BV605), then 
washed, fixed and permeabilised then stained for intracellular cytokines using INFγ-AF488, TNFα-
BV421 and IL-2-PE. Samples were analysed using a BD Fortessa machine and FACS Diva, FlowJo™, 
Pestle and SPICE software (see Supplementary Information).  
 
Statistical analysis 
Comparisons were made using parametric or non-parametric methods as appropriate using STATA 
v10. The sponsor of the study had no role in study design, data collection, analysis or writing of the 
report.  
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Results 
Of 65 individuals designated as having had contact with the infected patient, 45 category 3 contacts 
were found to have had possible direct skin contact with contaminated bodily fluids (vomit, sweat, 
blood, urine or cerebrospinal fluid (CSF)). None had evidence of percutaneous exposure and all 
would be categorised as “intermediate” in a more recently proposed exposure risk stratification[7]. 
Of these, 26 elected to receive vaccination following written informed consent and agreed to be 
followed as part of the observational GEVS Study. The median age of those vaccinated was 40 (range 
24-67). 15/26 (58%) were healthcare workers and 11/26 (42%) were household contacts. All 
individuals were followed up within the first 3 months following vaccination but attendance at 
subsequent follow-up clinics was incomplete due to movement of medical and nursing staff to other 
cities within the UK (Supplementary Table 2). No-one exposed to the virus became infected. All 
samples tested for EBOV and VSV were negative, including two febrile clinic attendees tested for 
EBOV prior to vaccination. 
Antibody responses: IgG indirect ELISA results are presented in Figure 3a as seroconversion (a 
positive antibody response at any time during the follow-up period) and individual responses 
detected at each follow-up visit to assess longevity of the response. By day 14, 39% had 
seroconverted. This rose to 87% by day 28 and 100% by 3 months. Such responses were not always 
sustained; one 68-year old individual developed a positive IgG response at 14 days post-vaccination 
but the level descended below the detection threshold at all further timepoints (Supplementary 
Figure 2). This was not associated with the onset of any form of illness or immunosuppressive 
treatment during this time period. Detectable antibody responses fell to 73% by 12 months post-
vaccination. Individual results are shown in Supplementary Figure 3. A positive anti-GP IgM 
response peaked at 14-28 days post-vaccination (Figure 3b) and negatively correlated with the 
emergence of neutralising antibody responses (Supplementary Figure 4). Neutralising antibody 
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responses were detectable in 6/16 (36%) individuals by day 14 and peaked at 9-12 months post-
vaccination with a detectable response in 9/12 (73%; Figure 3c). 
T-cell responses: IFNγ ELISpot responses to GP were detected at all timepoints, followed a similar 
pattern to neutralisation over time (Supplementary Figure 5) and peaked at 6 months post-
vaccination (Figure 3d).  Individual responses are shown in Supplementary Figure 6. 
Side effects: Side effects were common but mild in the majority of cases and were characterised by 
a syndrome of fatigue, myalgia, headache and arthralgia (Table 1). The presence of one symptom 
was strongly associated with the presence of others (Fisher exact test, p<0.0001). During the first 72 
hours of follow-up, 50% of individuals developed a fever ≥37.5oC, requiring in-hospital assessment 
and testing for EBOV. While the median duration of side effects was 0-1 days, a small number of 
patients developed long-standing symptoms of fatigue (up to 343 days), arthralgia (up to 261 days) 
and headache (up to 108 days). Two patients experienced long-lasting symptoms of arthralgia, one 
of whom had a diagnosis of osteoarthritis and flexor tendonitis thought to be unrelated to 
vaccination following specialist rheumatological review. Further details on cases of arthralgia are 
shown in Supplementary Table 3.  
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Symptoms of arthralgia, myalgia and fatigue occurring at the time of sampling were significantly 
associated with a higher proportion of CD8+IFNγ and CD4+IL2 secreting cells while headache was 
associated with higher CD4+IL2 (Figures 4a-d) and IFNγ ELISpot response. No significant association 
with IgM, IgG or neutralising antibody responses was found (Supplementary Table 4).  
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Discussion 
The risk of transmission of EBOV to household contacts and healthcare workers exposed to infected 
bodily fluids is high, particularly prior to diagnosis when the risks may not be fully appreciated. 
During the West Africa 2013-16 outbreak, several infected individuals travelled by air to other 
countries resulting in onward transmission. In Spain, a nurse became infected after caring for a 
patient transferred for specialist care and in the United States, two nurses became infected after 
contact with an undiagnosed infected traveller. In Nigeria, 20 people were infected (11 healthcare 
workers) following a single introduction[14]. No randomised studies on the use of PEP have been 
carried out in humans but vaccination and antiviral agents have been studied in exposed individuals 
on a case-by-case basis[6,7] and more recently in a large outbreak in DRC.  
The rVSV-ZEBOV vaccine is a highly effective vaccine that rapidly protects mice, hamsters, guinea 
pigs, non-human primates and humans from infection with EBOV when administered prior to 
exposure. In humans, ring vaccination with rVSV-ZEBOV at a dose of 2x107pfu was highly effective at 
preventing infection in contacts and contacts of contacts of individuals with EBOV infection in West 
Africa in a large phase III trial[15]. In this study, which initially involved an immediate and a delayed 
vaccine arm, no infections occurred 10 days after vaccination in any recipient (100% vaccine 
efficacy). As a result, randomisation was halted by an independent safety board and all subsequent 
participants in the study were offered immediate vaccination. Vaccination was carried out a median 
of 7.3 and 9.8 days following index patient symptom onset in the immediate and non-randomised 
vaccine rings respectively. Importantly, EBOV infection did occur in the 10-day period post-
vaccination and this was not reduced compared with the delayed vaccination arm. This indicates 
that the timing of the use of the vaccine is likely to be critical and would need to stimulate a 
protective immune response early within the median 9-10 day incubation period. 
In rhesus macaques (in whom infection is uniformly fatal with a more rapid onset of disease[6]), a 
single dose of the vaccine provides complete protection when given as little as 7 days before 
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challenge[4,16] and prevents infection in 50% when given as PEP 24 hours after infection[17]. 
Immunity is likely to be largely innate or antibody-dependent as depletion of CD4 or CD8+ cells post-
challenge does not abrogate protection[18]. 
The first use of rVSV-ZEBOV in a human was reported in 2011 following a high-titre needlestick 
exposure in a laboratory[5]. In this case, a single dose of 5x107pfu was administered 48 hours after 
the accident. At least 6 other individuals have now also received the vaccine, given 1-3 days post-
exposure, the majority having been exposed in Ebola Treatment Units (ETUs) during the 2014-2016 
West Africa outbreak[5,19,20]. All of these individuals were given a higher dose of vaccine and all 
developed significant side effects although none became infected (Table 2). 
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In this intervention, the 2x107pfu dose was selected as a balance between very high levels of 
reactogenicity found with the 1x108pfu dose and the lower immune responses found in individuals 
treated with lower doses in phase I and II studies[10,12,21]. We detected a higher incidence of 
symptoms in our study compared with these trials[10] but lower than that found in the cases 
described in Table 2. The high incidence of symptoms may be related to variation in genetic 
background and high levels of psychological stress. 
The risk of infection was likely to have been highest in those who had contact with body fluids from 
the index case. While blood and CSF tested positive by PCR, infectious virus was only isolated from 
the CSF where the titre was highest[22] (vomit, urine, saliva and rectal swabs all subsequently tested 
PCR-negative). In retrospect, the individuals with the highest potential risk of transmission were 
those exposed to CSF during the lumbar puncture procedure that took place 3 days before 
vaccination.  
The mechanism of protection following vaccination with rVSV-ZEBOV may involve innate, T-cell 
mediated and/or B-cell mediated responses[15,23,24]. We assessed the immune response by 
indirect ELISA, neutralisation with live ZEBOV(Mayinga strain), ELISpot and flow cytometry. There are 
no definite surrogates of immunity but such responses have been associated with protection from 
infection in macaques and humans. IgM responses peaked at day 14 while IgG seroconversion 
occurred in 39% at 14 days post-vaccination increasing to 87% by day 28 and 100% of individuals by 
3 months. The day 14 anti-GP seroconversion was lower than that found in rhesus 
macaques[4,25,26] and in human participants in pooled North American phase I studies which 
showed universal seroconversion by day 14[27]. In the phase II PREVAIL trials, 77-83% of 500 
individuals seroconverted within a month of vaccination[8,28]. We found the number of individuals 
with positive neutralising antibody responses were similar to those with anti-GP responses 
evaluated by ELISA. 75% of individuals were anti-GP positive at 1 year after vaccination and 73% had 
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positive neutralisation results. This is in keeping with a long-lasting effect found in other studies[29]. 
T cell responses directed against GP were also detected as described previously[24]. 
Future use of rVSV-ZEBOV must be balanced against the risk of side effects. It is a live vaccine and 
fever in vaccinated individuals has been found to be associated with evidence of replicating rVSV-
ZEBOV in blood[30]. The side effect profile of these Scottish vaccine recipients was similar to 
recipients in Switzerland with a higher prevalence of arthralgia than reported in phase I studies in 
Germany and Kenya. Arthralgia in Swiss participants lasted a median of 8 days (range 3-167 days; 
IQR:4-87 days)[12]. As in this study, symptoms were generally short-lived but were longer-lasting in 
2 patients. Headache, fatigue, myalgia and arthralgia were associated with the magnitude of T-cell 
response to pooled GP peptides with higher CD4+ production of IL2 and CD8+ production of IFNγ but 
not with antibody responses.   
There were several limitations to this study. Firstly, we cannot comment on efficacy of the vaccine as 
this was not a randomised controlled intervention following definitive virus exposure. However, we 
have demonstrated that Ebola vaccine used as PEP was immunogenic and relatively well-tolerated. 
Timing of administration is likely to be critical as some individuals did not develop a rapid immune 
response. While vaccination is a reasonable PEP strategy, other interventions such as the use of 
antiviral agents or newer vaccines may be warranted. 
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FIGURE LEGENDS 
 
Figure 1: Timeline of exposure period and vaccine delivery – following the 
recommendation to offer rVSV-ZEBOV vaccine by an expert panel, rapid approvals from the health 
board, MHRA and local ethics committee were obtained. 
 
Figure 2: Selection of individuals for vaccination and follow-up study 65 contacts of the 
index patients were assessed by a team of healthcare specialists, 45 of whom were asked to attend 
an outpatient follow-up clinic based on exposure risk. Of these, 26 received the rVSV-ZEBOV vaccine. 
 
Figure 3: Adaptive immune responses over time in vaccinated individuals Antibody 
responses 
measure by indirect ELISA, IgM, neutralisation and IFNγ ELISpot are plotted over time. Anti-GP 
seroconversion rates are shown with a cut-off of 0.03 IU/ml (3 x standard deviation of negative 
control). For antibody assays, negative control levels from unvaccinated individuals are plotted 
with a positive quality control (QC; dotted bars). Bars show the geometric mean with 95% CI. 
Numbers below the bars show the percentage of seroconverted people. Each dot is the average 
from two separate assays. For ELISpot, negative control represents unstimulated cells from 
vaccinated patients. P values < 0.05 (Mann Whitney U test) are highlighted. 
 
3a. Total anti-GP responses over time measured by indirect ELISA 
3b. Anti-GP IgM responses by ELISA over time 
3c. Neutralisation responses over time 
3d. T cell responses by IFNγ ELISpot to EBOV GP peptides over time 
 
 
Figure 4: Side effects related to T cell response CD4+ and CD8+ IFNγ and CD4+ IL2 responses 
in individuals with arthralgia, headache, fatigue and headache are shown. P values < 0.05 (Mann 
Whitney U test) are highlighted. 
 
4a. Arthralgia 
4b. Myalgia 
4c. Fatigue 
4d. Headache 
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TABLES 
Table 1: Side effects associated with rVSV-ZEBOV vaccination   
1a. Side effects specified in follow-up questionnaire   
Side effect Percentage  
(number) 
Duration 
(IQR,days) 
Severity (1-5) 
(IQR, days) 
Detail 
 
Fatigue 81% (21/26) 2 (1-5) 1 (1-2.5)  
Pain at injection 
site 
69% (18/26) 2 (1-4) 1 (1-2)  
Myalgia 69% (18/26) 2.5 (1-4.5) 1 (1-2)  
Headache 69% (18/26) 2 (1-4) 1 (1-2) 38% reported migraines 
Arthralgia 54% (14/26) 2.5 (1-17.75)  2 (1-2.75) Two patients with long-lasting 
symptoms 
Fever (≥37.5) 50% (13/26) - - All tested negative for EBOV 
Diarrhoea 15% (4/26) 1 (1-1) 1 (1-1)  
Vomiting 8% (2/26) 18.5 (1-36) 2.5 (1-4)  
Induration 0% (0/26) 0 (0-0) 0 (0-0)  
 
1b. Side effects volunteered during follow-up 
Other reported side effects 
 
% Related to vaccine 
Ophthalmic shingles 3% (1/26) Possible 
Fractured neck of femur 3% (1/26) Unrelated  
Dizziness 6% (2/26) Likely 
Sinusitis 3% (1/26) Unrelated 
Cervical lymphadenopathy 3% (1/26) Related (evaluated by ultrasound 
and too small for aspiration) 
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Table 2: Case reports/series of individuals treated with rVSV-ZEBOV vaccine 
Reference Exposure type Setting Timing of 
vaccination 
Dose of 
vaccine 
Outcome 
Gunther et al 2011
5
 High risk 
needlestick injury  
Laboratory 
(BSL4) 
48 hours 5 x 10
7
 pfu Uninfected 
Symptomatic 
Wong et al 2016
19
 High risk injury with 
glass  
Clinical  
(ETU) 
3 days 1x10
8
 pfu Uninfected 
Symptomatic 
Wong et al 2016
19
 Low risk needlestick 
injury  
Clinical 
(ETU) 
24 hours 1x10
8
 pfu Uninfected 
Symptomatic 
Wong et al 2016
19
 High risk injury with 
glass  
Clinical 
(ETU) 
27 hours 1x10
8
 pfu Uninfected 
Symptomatic 
Wong et al 2016; Lai 
et al 2015*
19,21
 
High risk 
needlestick injury 
Clinical 
(ETU) 
43 hours 1x10
8
 pfu Uninfected 
Symptomatic 
Wong et al 2016
19
 High risk 
needlestick injury 
Clinical 
(ETU) 
3 days 1x10
8
 pfu Uninfected 
Symptomatic 
Cnops et al 2015
20
 High risk 
needlestick injury 
Clinical 
(ETU) 
2 days 1x10
8
 pfu Uninfected 
Symptomatic 
*Same individual reported in two separate publications 
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Figure 1 v6 
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Figure 2 v6 
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Figure 3a-d 
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Figure 4a-d 
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